Streetbeat News

Stock Prices

F

GM

Ford Motor Co (NYSE:F) is experiencing bullish momentum ahead of its Q1 earnings report on April 24, with technical indicators largely supporting a positive outlook despite some cautionary signals. Wall Street anticipates an EPS of 50 cents and revenues of $40.7 billion. The stock has seen a modest year-over-year gain of 7.46% and is up 7.2% for the year. Analyst consensus rates Ford as a Buy with a target price of $13.75, though recent analyses suggest a potential 14.24% upside to $15. General Motors Co's (NYSE:GM) strong Q1 performance and raised outlook have also positively influenced Ford's stock.

Portfolio Pulse from Surbhi Jain

April 23, 2024 | 1:49 pm

FOSUF

FSNGF

TCOM

Fosun Tourism Group (FSNGF) is facing a post-Covid downturn with its shares trading near all-time lows, despite a slight increase in business volume at its Atlantis Sanya resort and Club Med chain. Reports earlier this year suggested that its parent company, Fosun International (FOSUF), might sell major assets to alleviate debt, casting uncertainty on FSNGF's future. Meanwhile, Trip.com (TCOM) has seen a 40% stock increase this year, outperforming FSNGF despite the latter's business volume rising nearly 50% from pre-pandemic levels.

Portfolio Pulse from The Bamboo Works

April 23, 2024 | 1:46 pm

MRK

Merck & Co's (NYSE:MRK) short interest has decreased by 15.38%, with 19.59 million shares sold short, representing 0.77% of its float. This decline in short interest could indicate a more bullish sentiment towards MRK among investors. Compared to its peers, MRK has a lower short interest percentage of float, with the average being 4.22%.

Portfolio Pulse from Benzinga Insights

April 23, 2024 | 1:45 pm

AAP

Advance Auto Parts (NYSE:AAP) has seen a decrease in short interest, now at 8.27% of its float, lower than the peer group average of 11.91%. This reduction from 4.36 million shares suggests a more bullish market sentiment towards AAP, despite short selling being a strategy betting on stock price declines. The current short interest represents a 17.96% drop and would take approximately 2.14 days to cover based on trading volume.

Portfolio Pulse from Benzinga Insights

April 23, 2024 | 1:45 pm

ISRG

Intuitive Surgical's (NYSE:ISRG) short interest has decreased by 3.96%, with 3.41 million shares sold short, representing 0.97% of its float. The current short interest suggests a bullish sentiment compared to its peers, with a peer group average of 4.21% short interest. This change in short interest could influence the stock's short-term performance.

Portfolio Pulse from Benzinga Insights

April 23, 2024 | 1:45 pm

SPY

The S&P Global Composite PMI for April registered at 50.9, a decrease from the previous month's 52.1, indicating a slower expansion in the composite sector.

Portfolio Pulse from Benzinga Newsdesk

April 23, 2024 | 1:45 pm

BA

GE

In a Reuters interview, GE Aerospace's CEO stated his commitment to serving Boeing as their best supplier, dismissing speculation about taking the Boeing CEO position. He confirmed that Boeing continues to receive engine deliveries at the same rate.

Portfolio Pulse from Benzinga Newsdesk

April 23, 2024 | 1:44 pm

BTCUSD

DOGEUSD

The Bitcoin Therapist, a popular Bitcoin newsletter writer, shared his entry into cryptocurrencies through a fortunate Dogecoin investment that led him to focus solely on Bitcoin. Initially investing in Dogecoin, he quickly shifted to Bitcoin after his investment grew, and despite Dogecoin's significant later gains, he has since focused exclusively on Bitcoin. Over the past 3.5 years, Bitcoin's price has increased by 270%, while Dogecoin's has surged by 4,670%.

Portfolio Pulse from Khyathi Dalal

April 23, 2024 | 1:43 pm

ABEO

The FDA issued a Complete Response Letter (CRL) to Abeona Therapeutics Inc (NASDAQ:ABEO) for its Biologics License Application (BLA) for prademagene zamikeracel (pz-cel), a treatment for recessive dystrophic epidermolysis bullosa (RDEB). The CRL cited the need for additional Chemistry Manufacturing and Controls (CMC) information but did not identify deficiencies in clinical efficacy or safety. ABEO shares dropped 45.10% to $4.04 following the announcement.

Portfolio Pulse from Vandana Singh

April 23, 2024 | 1:43 pm

FIVE

JP Morgan analyst Matthew Boss downgrades Five Below (NASDAQ:FIVE) from Overweight to Neutral and lowers the price target from $215 to $170.

Portfolio Pulse from Benzinga Newsdesk

April 23, 2024 | 1:39 pm